[
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).Primary outcomes\nThe primary outcome measure for this study is lesion classification, using a 3-point scale: benign, uncertain or malignant.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe Skin cancer Management with ARTificial Intelligence computer display: participant avatar indicating the lesion location.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "AI, artificial intelligence; eCRF, electronic Case Report Form.On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "If any lesions are to be monitored, participants will exit the study when either: (1) the monitored lesion(s) progress to biopsy at the 3-month or 6-month follow-up, and the histopathology results are received; (2) the monitored lesion(s) are classified as benign at the 3-month or 6-month follow-up or (3) the participant is lost to follow-up (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "On study completion, participants will continue to undergo routine surveillance depending on their level of risk and will receive treatment for all lesions as per Australian Guidelines (figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]